Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for chronic nausea in advanced cancer
NCT05403580Phase 3Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Jun 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of olanzapine in nausea ((none)), Vomiting, sponsored by Mayo Clinic. Planned start Jun 2022; status: withdrawn.
02
Drugs
olanzapine
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on NCT05403580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403580.